This is the authors' abstract. We don't add key points for this paper.
The emergence of polymyxin-resistant carbapenem-resistant Klebsiella pneumoniae (CRKP) severely limits clinical treatment options and poses a significant threat to anti-infective therapy. In this study, we investigated the genetic characteristics of an IncHI5-like plasmid co-harboring blaNDM−1 and blaOXA−1 in an mcr-8.1-positive clinical CRKP isolate using a combination of MIC testing, conjugation experiments, bacterial whole-genome sequencing, and bioinformatics analyses. The ST626 CRKP strain KP19-2581, isolated from a human clinical infection, exhibited a multidrug-resistant (MDR) phenotype. Whole-genome sequencing revealed that the colistin resistance gene mcr-8.1 was located on an IncFIA/IncFII plasmid, flanked by the conserved structure IS903B-orf-mcr-8.1-orf-IS903B. In addition, strain KP19-2581 carried a novel IncHI5-like MDR plasmid, designated pKP19-2581-367k-HI5-NDM1, which co-harbored the blaNDM−1 and blaOXA−1 genes. This plasmid contained two MDR regions, harboring a diverse array of resistance genes across multiple antibiotic classes. The dissemination of blaOXA−1 in variable region is related to the structure of class 1 integron, while IS26 mediates the integration of blaNDM−1 on IncHI5-like plasmid. Notably, this is the first report of an IncHI5-like plasmid carrying both blaNDM−1 and two copies of blaOXA−1, along with multiple resistance genes and insertion sequences. Given its potential to acquire additional resistance determinants, this plasmid may serve as a reservoir for further antimicrobial resistance evolution, underscoring the urgent need for surveillance of IncHI5 plasmids to mitigate their clinical and epidemiological impact.
No takes yet. Share an insight, caveat, or question.
Liu et al. (2025) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: